Clinical Trials at Tays Cancer Centre

Contact Information: FONK(at)pshp.fi
(Please replace (at) with @-symbol when sending e-mail.)

Open for inclusion = Open for inclusion
Closed for inclusion = Closed for inclusion

Cancer type

Title of the study

Acute myeloid leukemia (AML) Open for inclusion

R20076M HOVON 156 AML

AMLSG 28-18: Rimpiläinen

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance  in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

Acute myeloid leukemia (AML) Closed for inclusion

R20052M

VenEx: Rimpiläinen

Two-Stage, Two-Arm, Open-Label Phase II Study of Venetoclax in Combination with Azacitidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening.

Acute myeloid leukemia (AML)

Closed for inclusion

R17112M

VIALE-A: Rimpiläinen

A randomized, double-blind, placebo controlled, phase III study of Venetoclax in combination with Azacitidine versus Azacitidine in treatment naïve subjects with acute myeloid leukemia who are ineligible for standard induction therapy.

Acute myeloid leukemia (AML) Open for inclusion

R21043M

HO150: Rimpiläinen

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by  maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Acute lymphoblastic leukemia (ALL) Open for inclusion

R20054M

ALLTogether: Rimpiläinen

ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic  leukaemia (ALL). (Clinical phase 3).

Acute lymphoblastic leukemia (ALL)

Closed for inclusion

R09080

NOPHO: Rimpiläinen

Treatment protocol for children (1.0 - 17.9 years of age) and young adults (18-45 years of age) with acute lymphoblastic leukemia. Phase III trial.

Bladder cancer Closed for inclusion

R19084M

Ca170-078: Moisander

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy  plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle- Invasive Bladder Cancer.

www.clinicaltrials.gov

Bladder cancer Open for inclusion

R18164M

KEYNOTE-676: Tammela

A phase III, randomized, comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is persistent or recurrent following BCG induction.

www.clinicaltrials.gov

Bladder cancer Closed for inclusion

R15126M

WO29636 /Imvigor: Tammela

A phase III, open-label, multicenter, randomized study of MPDL3280A (ANTI-PD‑L1 ANTIBODY) versus observation as adjuvant therapy in patients with PD‑L1-Selected, high-risk muscle-invasive bladder cancer after cystectomy.

Breast cancer Open for inclusion

R21064M

Kate3:Tanner

A randomized, multicenter, double-blind, placebo- controlled phase III study of the efficacy and safety of trastutsumab emtamsine in combination with atetsolizumab or placebo in positive locally advanced or metastatic breast cancer who have receideb prior trastuzumab (+/- pertuzumab)and taxane-based therapy (KATE3)

www.clinicaltrials.gov

Breast cancer Open for inclusion

R21166M

GO42784, lidERA: Tanner

A phase III, randomized, open label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician`s Choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer

www.clinicaltrials.gov

Breast cancer Open for inclusion

R21016M

AL-2001/IXABEPILONE: Tanner

Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected  by the ixabepilone Drug Response Prediction (DRP) after failure of an anthracycline and a taxane.

www.clinicaltrials.gov

Breast cancer Open for inclusion

R16008M

BOLD: Tanner

A randomized phase III study comparing trastuzumab, pertuzumab,pertuzumab plus docetaxel followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2 positive breast cancer.

Breast cancer Closed for inclusion

R07195M

SOLD: Kellokumpu-Lehtinen 

A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single agent trastuzumab as adjuvant treatments for early breast cancer.

Breast cancer Closed for inclusion

R17078M

Monarch I3Y-MC-JPCF:  Tiainen

A randomized, open-label, phase III study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone positive, human epidermal receptor 2 negative breast cancer.

Breast cancer,
HER2 neg
Closed for inclusion

R21045M

AMEERA 5: Tanner

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast cancer,
HER2 neg
Closed for inclusion

R18198M

Stesides: Tanner

Safety and pharmacokinetics of ODM-209 in patients with metastatic castration-resistant prostate cancer or estrogen receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer.  

Breast cancer,
HER2 neg
Closed for inclusion

R19038M

CLEE011A2207/Tanner

A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women  with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.

Breast cancer,
HER2 neg
Closed for inclusion

R19083M

1280.18: Tanner

An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally  advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.

Breast cancer,
HER2 neg, ER pos
Open for inclusion

R200062M

Ca209-7FL: Tiainen

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy  and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.

www.clinicaltrials.gov

Breast cancer, triple neg Closed for inclusion

R18072M

MO39193/Impassion 132: Tanner

A phase III randomized, placebocontrolled multi-center study of the efficacy and safety of atezolizumab in combination with chemotherapy for patients with early relapsed triple-negative breast cancer.

Breast cancer, triple neg Closed for inclusion

R16132M

MK-3475-173 (KEYNOTE 173): Tanner

A phase 1b study to evaluate safety and clinical activity of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) –

Breast cancer Open for inclusion

R21142M:Tanner

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated  Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

www.clinicaltrials.gov

Breast cancer Closed for inclusion

R21137M

EPIK- B5/ CBYL719C2303: Tanner

A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

www.clinicaltrials.gov

Breast cancer Open for inclusion

R22104M

CBYL719G12301-EPIK-B2: Tanner 

A two-part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess to efficacy and safety of Albelisib (BYL719)in combination with trastutzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation.

www.clinicaltrials.gov

Cancer of Unknown Primary Closed for inclusion

R18017M

CUPISCO MX39795: Tanner

A phase II, randomized, activecontrolled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy.  

www.clinicaltrials.gov

Cervical cancer Open for inclusion

R21138M

SGNTV-003:Auranen  

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator´s Choice Chemotherapy in second or hird-Line Recurrent or Metastatic Cervical Cancer Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer.

www.clinicaltrials.gov

CLL Open for inclusion

R19101M

ASSURE: Luopajärvi

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib  (ACP-196) in Subjects with Chronic Lymphocytic Leukemia.

CLL Closed for inclusion

R18015M

HO141 CLL: Luopajärvi

A prospective,  multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.

CLL Closed for inclusion

R17047M

CLL13 GAIA: Luopajärvi

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.

CLL Kliiniset tutkimukset -avoinna

R21145M

CLL17: Luopajärvi

A Phase 3 multicentre, randomized, prospective, open- label trial of Ibrutinib monotherapy versus fixed- duration Venetolax plus Obinutuzumab versus fixed- duration Venetolaclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Colorectal cancer Closed for inclusion

R12116M

RAXO: Österlund

A population-based prospective study to evaluate clinical behaviour, resectability and survival in metastatic colorectal cancer patients in Finland.

Colorectal cancer Closed for inclusion

R16017M

MK-3475-177: Salminen

A phase III study of pembrolizumab (MK-3475) vs chemotheraby in microsatellite instability-high (MSI-H) or mismatch repair deficient (DMMR) stage IV colorectal carcinoma.

Colorectal cancer Open for inclusion

R12117M

AXOAXI: Salminen

Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer.

Colorectal cancer Closed for inclusion

R16138M

NORDIC-9: Salminen

Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer. Phase II study.

Colorectal cancer Open for inclusion

R22001M

MIRATI-KRYSTAL: Salminen

A Randomized Phase 3 study of MRTX849 in Combination with cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression on or After Standard First-Line Therapy

www.clinicaltrials.gov

Colorectal cancer Open for inclusion

R21151M

COLSTAR: Österlund

A Randomised, open-label, multi-cenre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tibiracil to trifluridine/tibiracil single agent with a Safety Lead-In part in participantsa with KRAS7NRAS and BRAF wild type metastatic colorectal cancer previously treated with standard treatment and anti EGFR therapy

www.clinicaltrials.gov

Colorectal cancer Open for inclusion

R22069M

Breakwater C4221015: Salminen 

An open-label, Multicenter, Randomized Phase 3 Study Of First-Line encorafenib Plus cetuximab With Or Without Chemoterapy Versus Standard Of Care Therapy With A Safety Lead-in Of encorafenib and cetuximab plus Chemoterapy In Participants With Metastatic BRAF V600E-Mutant Colorectal Cancer.

www.clinicaltrials.gov

Endometrial cancer Open for inclusion

R21042M

MK3475-B21: Auranen 

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21  / ENGOT-en11 / GOG-3053).

www.clinicaltrials.gov

Endometrial cancer Kliiniset tutkimukset - ei uusia potilaita

R19103M

RUBY: Auranen

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer.

Endometrial cancer Closed for inclusion

R16187M

PALEO: Auranen

A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus placebo in combination with Letrozole for patients with estrogen receptor positive advanced or recurrent endometrial cancer.

Endometrial cancer Closed for inclusion

EN2-DGCG: Auranen

Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer.

Endometrial cancer Open for inclusion

R22019M

MK-3475-C93: Auranen

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair deficient (dMMR9 Advanced or Recurrent Endometrial  Carcinoma in the Fisrt-line Settings (KEYNOTE-C93/GOG-3064/ENGOT-en15)

www.clinicaltrials.gov

GIST Open for inclusion

R15127M

GIST SSGXXII: Paunu

Three versus five years of adjuvant Imatinib as treatment of patients with operable GIST with a high risk for recurrence: a randomised phase III multicenter study by the Scandinavian Sarcoma Group.

www.clinicaltrials.gov

Head and neck carcinoma Closed for inclusion

R15025M

MK-3475-048: Reinikainen

A phase III clinical trial of Pembrolizumab (MK-3475) in first line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.

Head and neck carcinoma Open for inclusion

R22015M

NANORAY-312: Skyttä, Lahtela 

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma.

www.clinicaltrials.gov

Leukemia

(AML, MDS, KMML)

Open for inclusion

R22065M 

BEXMAB: Rimpiläinen

Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with Azacitidine or Azacitidine/Venetoclax in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia.

Liposarcoma Open for inclusion

R22060M

1403-0008: Lyly-Yrjänäinen

A Phase Ii/III, randomized, open -label, multi-center study of BI907828 compared to doxorubicin as first line treatment of patients with advanced dedifferential liposarcoma

www.clinicaltrials.gov

Liver cancer Open for inclusion

R21105M

MO42541/Imbrave251: Österlund

A phase III, open-label, randomized study of atetzolizumab with lenvatinib or sarafenib versus lenvatinib or sorafenib alone in hepatocellular carsinoma previously treated with atetzolizumab and bevacizumab.

www.clinicaltrials.gov

Lung cancer Open for inclusion

R19102M

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736): Skyttä

 An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patients with T1-2N0M0 Non-small Cell Lung Cancer (NSCLC).

www.clinicaltrials.gov

Lung cancer Open for inclusion

R20069M

Apollomics INC APL-101-01: Ahvonen

Phase 1/2 Multicenter study of the safety, pharmacokinetics and preliminary efficacy of APL-101 in subjects with Non small  Cell lung cancer with c-met EXON 14 skip mutations and c-Met dysregulation advanced solid tumors.

www.clinicaltrials.gov

Lung cancer Open for inclusion

R20163M

DART: Ahvonen

Durvalumab (MEDI4736)after chemoradiotherapy (DART)for NSCLS patient-  a phase II translational anb biomarker Study investigating PDL1 positive and negative patients.

www.clinicaltrials.gov

Lung cancer Kliiniset tutkimukset - ei uusia potilaita

R21079M

MK7684A-002: Ahvonen

A Phase 2, multicenter, randomized study to compare the efficacy and safety of MK-7684A  or MK-7684A plus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum douplet chemotherapy and immunotherapy.

Lung cancer Open for inclusion

R22021M

MO43576/Imscin002: Ahvonen

A Randomized, multicenter, open-label cross-over study to evaluate participant and healthcare professional reported preference for subcutaneous atetzolizumab compared with intravenous atatsolizumab formulation in participants with non-small cell lung cancer.

www.clinicaltrials.gov

Lung cancer Open for inclusion

R22017M

213824: Ahvonen

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer.

www.clinicaltrials.gov

Lymphoma Kliiniset tutkimukset - ei uusia potilaita

R18209M

FIORELLA: Pollari

Randomized phase II trial on Fitness and comorbidity-  tailored treatment in elderly patents with newly diagnosed primary CNS lymphoma.

Lymphoma Kliiniset tutkimukset - ei uusia potilaita

R17145M

BIO-CHIC: Pollari

Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma (NLG-LBC-06).

Lymphoma Closed for inclusion

R18211M

SAKK: Pollari

Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.

Lymphoma Open for inclusion

R21062M

GENMAB3013-01: Pollari

A Phase 1/2, Open-Label,  Dose-Escalation Trial of GEN3013 in patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

www.clinicaltrials.gov

Lymphoma Open for inclusion

R21117M

Hutchison-2018-532-00US1: Pollari

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary

Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma.

www.clinicaltrials.gov

Lymphoma Closed for inclusion

R21118M

Hutchison-2018-689-00US1: Pollari

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-689 in Patients with Relapsed or Refractory Lymphoma.

www.clinicaltrials.gov

Lymphoma

Diffuse Large B-cell Lymphoma

Open for inclusion

R21106M

MO40598, PolarGO: Pollari

A phase III, open label, multicenter, randomized study evaluating the safety and efficacy of polatuzumab vedotin in combination with rituximab plus gemsitabine plus oxaliplatin (R-GEMOX) versus R-GEMOX alone in patients with relapsed/refractory diffuse large B-cell lymphoma

www.clinicaltrials.gov

Lymphoma
Diffuse Large B-cell Lymphoma
Open for inclusion

R16108M

MOR00208/B-MIND: Keskinen

A phase II/III, randomised, multicentre study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) – B-MIND

Lymphoma
Diffuse Large B-cell Lymphoma
Open for inclusion

R20119M

NLG-07 (POLAR BEAR): Pollari

R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma  Group phase III trial.

www.clinicaltrials.gov

Lymphoma
Diffuse Large B-cell Lymphoma
Open for inclusion

R21080M

GCT3013-05: Pollari

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.

www.clinicaltrials.gov

Lymphoma
Non-Hodgkin
Open for inclusion

R21082M

Genmab3013-02: Pollari

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma.

www.clinicaltrials.gov

Lymphoma
Non-Hodgkin
Closed for inclusion

R17032M

CHRONOS-4: Pollari

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor Copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL)

Lymphoma

Mantle cell lymphoma

Closed for inclusion

R19118M

ENRICH: Pollari

Randomised, open label study of Rituximab/Ibrutinib  vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Lymphoma Open for inclusion

R21134M

InMIND(INCMOR0208-301): Pollari


A phase 3, randomized, double-blind, Placebo-controlled,  multicenter Study to evaluate the efficacy and Safety of tafasitamab plus lenalidomide in addition to rituksimab versus lenalidomide in addition to rituksimab in patients with relapsed/refractory (R/R) Follicular lymphoma grade 1 to 3a or R/R marginal zone lymphoma.

www.clinicaltrials.gov

Melanoma Closed for inclusion

R13091M

Ca209-067: Skyttä

A Phase 3, randomized, double-blind study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in subjects with previously untreated unresectable or metastatic melanoma.

Melanoma Closed for inclusion

R15089M

CA209-238: Skyttä

A phase III, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus Ipilibumab after complete resection of st IIIb/c or st IV melanoma in subjects who are at high risk for recurrence.

Melanoma Closed for inclusion

R161334

MK3475-054 (KEYNOTE-054): Skyttä

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody MK-3475 versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC Melanoma Group.

Melanoma Closed for inclusion

R18084M

CA224-047: Skyttä

A randomized, double-blind phase II–III study of BMS-986016 combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma.

Melanoma Kliiniset tutkimukset - ei uusia potilaita

R19137M

CA209-76K / Skyttä

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.

Melanoma Closed for inclusion

R20134M

Nektar: Skyttä

A Phase  3, randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.

Melanoma Closed for inclusion

R21152M

Ca224-098: Skyttä

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

www.clinicaltrials.gov

Melanoma Open for inclusion

R22103M

Starboard C4221016: Skyttä

A Phase 3, randomized, double-blind study of encorafenib and binimetinib plus pembrolizumab versus placebo plus pembrolizumab in participants with BRAF V600E/K mutation-positive metastatic or unresectable locally advanced melanoma. 

www.clinicaltrials.gov

Myeloma Closed for inclusion

R18039M

Myeloma: IRd NMSG 23/15: Sankelo

A prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients.

Myeloma Open for inclusion

KeD: Sankelo

Phase 2 study of carfilzomib + elotuzumab +dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines.

Myeloma Open for inclusion

R22064M

MAGNETISMM-5: Sankelo

An open-label, 3-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of Elranatamab (PF-06863135) monotherapy and Elranatamab+Daratumumab versus Daratumumab+Pomalidomide+Dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy including lenalidomide and a proteasome inhibitor.

www.clinicaltrials.gov

Osteosarcoma Open for inclusion

R20053M

OLIE: Palmu

A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficasy and safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory  Osteosarcoma.

Ovarian cancer Open for inclusion

R20048M

AGO-OVAR 2.29: Auranen

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT trial.

www.clinicaltrials.gov

Ovarian cancer Closed for inclusion

R17105M

IMagyn050: Auranen

A phase III, multicenter, randomized, study of Atezolizumab versus Plasebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab to patients with newly-diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.

Ovarian cancer Closed for inclusion

R16061M

AVANOVA: Auranen

Niraparib vs. niraparib-bevacizumab combination in women with  platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer. Phase II trial.

Ovarian cancer Closed for inclusion

R18152M

Tesaro FIRST: Auranen

A randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer.

Ovarian cancer Closed for inclusion

R16104M

Tesaro PRIMA: Staff

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response on front-line platinum-based chemotherapy.

Ovarian cancer Closed for inclusion

EWOC-1: Auranen

Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.

Ovarian cancer Closed for inclusion

R16064M

PAOLA: Mäenpää

Platinum, avastin and olaparib in first line treatment of patients with advanced ovarian/fallopian tube/peritoneal cancer. Phase III trial.

Ovarian cancer Closed for inclusion

R11119M

INOVATYON: Auranen

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum. Phase III trial. 

Ovarian cancer Closed for inclusion

R18189M

OPINION: Staff

A phase IIIb, single-arm, ppen-label multicentre study of Olaparib maintenance monotherapy in platinum sensitive relapsed non- germline BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.

Ovarian cancer Open for inclusion

R21131M

EPIK-O: Auranen

A Phase III, multi-center, randomized (1:1), open- label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.

www.clinicaltrials.gov

Ovarian cancer Open for inclusion

R22077M 

DOVACC: Auranen 

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736)  and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

www.clinicaltrials.gov

Pancreatic adenocarcinoma Closed for inclusion

R14070M

APACT: Salminen

A phase III, multicenter, open-label randomized study of NAB-PACLITAXEL plus GEMCITABINE alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma.

Pancreatic adenocarcinoma Open for inclusion

R22058M

CNIS793B12301: Salminen 

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

www.clinicaltrials.gov

Prostate cancer Closed for inclusion

R20107M

MK-3475-991: Jukkola

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants  With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Prostate cancer Closed for inclusion

R18198M

Stesides: Tanner

Safety and pharmacokinetics of ODM-209 in patients with metastatic castration-resistant prostate cancer or estrogen receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer.  

Prostate cancer Open for inclusion

R19098M

CYPIDES: Tanner

Safety and pharmacikinetics of ODM- 208 in patients with metastatic  castration-resistant prostate cancer.

www.clinicaltrials.gov

Prostate cancer Open for inclusion

R21123M

Talapro 3: Tammela

A phase 3, randomized, double-blind, study of Talazoparib with Enzalutamide versus placebo with Enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer.

Prostate cancer Closed for inclusion

R19062M

Talapro-2: Tammela

A Phase 3 randomized double-blind placebo-controlled study of talazoparib in combination with enzalutamide in men with metastatic castration resistant prostate cancer.  

Prostate cancer Closed for inclusion

R18020M

Astellas: Tammela

A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study.

Prostate cancer

Closed for inclusion

R16033H

9785-CL-0403 Arches : Tammela

A multinational, phase III, randomized, double-blind, placebo-controlled efficacy and safety study of Enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC), protocol number 9785-CL-0335

Prostate cancer

Closed for inclusion

R14009

ESKO: Reinikainen

Radiotherapy in prostate cancer

Prostate cancer

Closed for inclusion

R16118M

ODX-003: Tammela

A randomised, double-blind, dose finding, repeat dose phase II multicentre study of ODX for the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases.

Prostate cancer

Closed for inclusion

R15062M

MDV3100-13 /Embark: Tammela

A phase III, randomized, efficacy and safety study of Enzalutamide plus Leuprolide, Enzalutamide monotherapy, and placebo plus Leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy.

Prostate cancer

Closed for inclusion

R16201M

ARASENS: Tammela

A randomized, double-blind, placebo-controlled phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and Docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Prostate cancer

Closed for inclusion

R13101M

MDV3100-14 /PROSPER: Tammela

A multinational, phase III, randomized, double-blind, placebo-controlled, efficacy and safety study of Enzalutamide patients with nonmetastatic castration-resistant prostate cancer.

Prostate cancer

Closed for inclusion

R14049M

Bayer 15396: Paunu

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with Abiraterone acetate and Prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Prostate cancer

Closed for inclusion

R16072M

KEYNOTE-199: Kellokumpu-Lehtinen

Phase II trial of Pembrolizumab (MK-3475) in subjects with metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy.

Prostate cancer

Closed for inclusion

R06170M

AdRad: Kellokumpu-Lehtinen

A randomized adjuvant phase III trial of six cycles of Docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiotherapy (SPCG-13)

Prostate cancer Closed for inclusion

R19120M

RhoVac/Tammela

 A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer.

Prostate cancer Open for inclusion

R20132M

Radiant:Tammela

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant  prostate cancer (mCRPC) progressing on/after one line of NAH.

Prostate cancer Open for inclusion

R20101M

Bayer ROS: Tammela

An open-label, single arm, roll-over study to provide  continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies.

Renal Cell Carcinoma Open for inclusion

R21059M

MK-6482-012: Kankaanranta

An open-label, randomized phase 3 study to evaluate efficacy and safety of Pembrolizumab (MK-3475) in combination with Belzutifan (MK6482) and Lenvatinib (Mk7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib ad first- line treatment on participants with advanced clear renal cell carcinoma.

www.clinicaltrials.gov

Renal Cell Carcinoma Closed for inclusion

R19116M

EXELIXIS: Kankaanranta

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk.

Renal Cell Carcinoma Closed for inclusion

R21065M

Ca209-67T: Kankaanranta

A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who  Have Received Prior Systemic Therapy.

www.clinicaltrials.gov

Renal Cell Carcinoma Closed for inclusion

R15010M

Ca209-214:Kellokumpu-Lehtinen

A Phase 3, randomized, open-label study of Nivolumab combined with Ipilimumab versus Sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma.

Renal Cell Carcinoma

  Closed for inclusion

R17092M

KEYNOTE-564: Kankaanranta

A phase III, randomized, double-blind, placebo-controlled clinical trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy.

Renal Cell Carcinoma Closed for inclusion

R20039M

MK-6482-005: Pollari

An Open-label, Randomized Phase 3 Study of MK-6482  Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapiesx.

Renal Cell Carcinoma Open for inclusion

R22034M

MK-6482-022: Kankaanranta

A Multi-center, Double-Blind, Randomized Phase 3 study to Compare the Efficacy and Safety Beltuzifan(MK-6482) plus Pembrolizumab (MK-3475) Verusu Palcebo plus Pembrolizumab, in the Adjuvant Treatment of clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy( 6482-022)

www.clinicaltrials.gov

Renal Cell Carcinoma Open for inclusion

R21063M

MK-6482-011: Kankaanranta

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

www.clinicaltrials.gov

Solid tumors Open for inclusion

R21153M

INCB 99318-122: Tanner

A phase I study exploring the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB099318 in participants with select advanced solid tumors

www.clinicaltrials.gov

Solid tumors Open for inclusion

R19126M

MATINS: Mäenpää, Skyttä, Tanner

A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced  Solid Tumours.

www.clinicaltrials.gov

Platinum-resistant serous ovarian cancer Closed for inclusion

R21109M

Mersana: Auranen

A Phase 1b/2, First-in-Human,  Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.

www.clinicaltrials.gov

Urothelial carcinoma Open for inclusion

R18095M

BAY 1163877: Kellokumpu-Lehtinen & Sormunen

A randomized, open label, multicenter Phase II-III study to evaluate the efficacy and safety of rogaratinib (BAY 163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy.

Urothelial carcinoma Closed for inclusion

R15126M

WO29636: Tammela

A phase III, open-label, multicenter, randomized study of atetzolizumab (ANTIPD-L1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carsinoma after surgigal resection.

Open for inclusion

R18212M

Bayer 16996: Tanner

A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride.

Open for inclusion

R22012M

FINPROVE: Tanner, Auranen

The Finnish National Study to Facilitate Patient Access to Targeted Anti-Cancer Drugs to determine the Efficacy in Treatment of Advanced Cancer with a Known Molecular Profile

www.clinicaltrials.gov